Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) Total Liabilities (2022 - 2026)

Lexeo Therapeutics' Total Liabilities history spans 2 years, with the latest figure at $26.3 million for Q4 2023.

  • On a quarterly basis, Total Liabilities rose 5.1% to $26.3 million in Q4 2023 year-over-year; TTM through Dec 2023 was $26.3 million, a 5.1% increase, with the full-year FY2023 number at $26.3 million, up 5.1% from a year prior.
  • Total Liabilities hit $26.3 million in Q4 2023 for Lexeo Therapeutics, down from $32.5 million in the prior quarter.
  • Over the last five years, Total Liabilities for LXEO hit a ceiling of $143.6 million in Q2 2023 and a floor of $25.0 million in Q4 2022.